Trial record 59 of 546 for: "Viral Infectious Disease" | "Peginterferon alfa-2a"
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02515279|
Recruitment Status : Completed
First Posted : August 4, 2015
Results First Posted : February 10, 2016
Last Update Posted : April 10, 2017
Information provided by (Responsible Party):
|Study Design||Observational Model: Cohort; Time Perspective: Prospective|
Drug: Peginterferon alfa-2a
The sustained viral response that had to be filled out 6 months (or later) after the end of treatment was documented poorly due to reasons such as participants that were lost to follow-up or the study closure was before the visit date for the SVR.